ExploreWatchlistsPricing
  1. JP-listed companies
  2. Momotaro-Gene Inc.
  3. Financials
  4. Cash from operations

Momotaro-Gene Inc. (E33052)

Market cap
P/E ratio
Momotaro Genen develops innovative gene therapy drugs using the REIC cancer suppressor gene discovered at Okayama University to selectively kill cancer cells.
SummaryFinancialsDividendsHistoryWorkforce
Period EndCash from operations (Million JPY)YoY (%)
Mar 31, 2023-198-18.63%
Mar 31, 2022-244-37.90%
Mar 31, 2021-392+30.38%
Mar 31, 2020-301-22.98%
Mar 31, 2019-391+14.73%
Mar 31, 2018-341+87.42%
Mar 31, 2017-182+17.06%
Mar 31, 2016-155-1656.64%
Mar 31, 201510-190.82%
Mar 31, 2014-11-35.61%
Mar 31, 2013-17+4059.76%
Mar 31, 2012-0-99.65%
Mar 31, 2011-117-35.52%
Mar 31, 2010-182+343.40%
Mar 31, 2009-41

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat